A committee said the volrustomig combination was unlikely to reach either of the primary endpoints for the trail, but the company said other Phase 3 volrustomig trials would continue as planned.
A committee said the volrustomig combination was unlikely to reach either of the primary endpoints for the trail, but the company said other Phase 3 volrustomig trials would continue as planned.